Gimme Care
Editorial reviewLow, honest pricing on both molecules from a LegitScript-verified nationwide operator.
Visit Gimme CareHead-to-head verdict
Two GLP-1 providers, ruled side by side on The Verdict Score — our published six-factor rubric. Same yardstick, no pay-to-win placement.
Low, honest pricing on both molecules from a LegitScript-verified nationwide operator.
Visit Gimme CareA polished, high-disclosure compounded program with strong nationwide coverage.
Visit EdenEden takes it with a higher Verdict Score — 91/100 to 85/100 (grade A− vs B). People who prioritize a vetted, high-transparency provider over the lowest sticker price. Gimme Care still earns its place — value shoppers who want a verified pharmacy without paying for frills they won't use.
Neither of these is our overall #1. That title goes to CoreAge Rx (94/100) — the most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
| Metric | Gimme Care | Eden |
|---|---|---|
| Verdict Score | 85/100 | 91/100 |
| Grade | B | A− |
| Semaglutide | $130/mo | $239/mo |
| Tirzepatide | $163/mo | $349/mo |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | No | No |
| Relationship | Editorial | Partner |
What we like
The caveats
What we like
The caveats
Also worth a look
Value shoppers who want a verified pharmacy without paying for frills they won't use.
Visit Gimme Care Read the full Gimme Care review →Our pick — visit
People who prioritize a vetted, high-transparency provider over the lowest sticker price.
Visit Eden Read the full Eden review →Or browse the full comparison hub and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.